Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
In vitro characterization of pharmacological chaperones of the dopamine transporter as an approach to treat Dopamine Transporter Deficiency Syndrome.
FY 2016-17
Summary
Dopamine Transporter deficiency syndrome is a newly identified genetic disorder that results in severe movement disorders withthe afflicted generally not living past adolescence.Patients suffering from this disease either have anabsence or misfunction of a key brain protein, the dopamine transporter, resulting from mutations in this protein. Recent studies have shown that a commonly prescribed antidepressant, bupropion, can rescue the function of some mutants in cellular assays. In this current study, we propose to assess the effects of bupropion and its analogues on all dopamine transportermutations identified to date. Furthermore, we aim to determine the underlying molecular mechanisms by which bupropion and its analogues increase the amount of the dopamine transporter. These experiments will be carried out using cellular assays.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367345
Name
Sutton Charles D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
In vitro characterization of pharmacological chaperones of the dopamine transporter as an approach to treat Dopamine Transporter Deficiency Syndrome.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behavioural Pharmacology; Bupropion; Dopamine Neurotransmission; Dopamine Transporter; Heterologous Cells; Misfolding Mutations; Pharmacological Chaperones; Transgenic Animals
Abstract
Dopamine Transporter deficiency syndrome is a newly identified genetic disorder that results in severe movement disorders withthe afflicted generally not living past adolescence.Patients suffering from this disease either have anabsence or misfunction of a key brain protein, the dopamine transporter, resulting from mutations in this protein. Recent studies have shown that a commonly prescribed antidepressant, bupropion, can rescue the function of some mutants in cellular assays. In this current study, we propose to assess the effects of bupropion and its analogues on all dopamine transportermutations identified to date. Furthermore, we aim to determine the underlying molecular mechanisms by which bupropion and its analogues increase the amount of the dopamine transporter. These experiments will be carried out using cellular assays.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sutton, Charles D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~